2025-05-08-Jefferies-世代生物（GBIO）_第一季度专注于主要RNAi靶点和2025年年中自身免疫适应症披露_10页_251kb

报告摘要

Company: Generation Bio is a preclinical-stage genetic medicine company focusing on non-viral gene therapies.
Founded in 2016, it operates in Cambridge, MA.

Current Focus: siRNA delivery via ctLNP for T-cell-driven autoimmune diseases.
- Disclosing target(s) and indications in mid-2025.
- IND submission planned for H2 2026.
- Cash runway of $158M extends to H2 2027.
Technology: Unique ctLNP platform targets T cells without affecting the broader immune system.
Analyst View:
- Rating: "BUY" with a price target of $4.00 (approx. 925% upside from $0.39).
- Catalysts: Disclosure of targets/indications, IND submission, preclinical data, and timeline to clinical trials.
- Stock down ~63% YTD vs. broader market (XBI -14%), expected rebound due to clearer strategy and catalysts.
Financials:
- Negative EPS for 2025E and 2026E, cash flow projections highlight runway needs.
- Revenue from collaborations and royalties expected to grow initially.
Pipeline:
- Potential T-cell autoimmune indications: alopecia, IBD, GCA, AIH, etc.
- Other programs include hemophilia A (preclinical) and SCD/TDT (targeting partnerships).
Investment Thesis:
- Strong differentiation in siRNA delivery (no liver bottleneck).
- White space in T-cell autoimmune therapies.
- Platform potential used in valuation, with risks tied to early-stage technology and competition.

Covering Analysts: Farzin Haque, Ph.D., Maury Raycroft, Ph.D., Amin Makarem, Ph.D., Amy Qian, Ph.D.
Risks:
- Untested non-viral gene therapy platform.
- Competition in gene therapy and gene editing fields.
- Distant profitability and pricing challenges.